micronavigation ELN path item Leukemias path item CML path item Publications  · 
Workpackage 4

Publications



  1. Baccarani M, Martinelli G, Rosti G, Trabacchi E, Testoni N, Bassi S, Amabile M, Soverini S, Castagnetti F, Cilloni D, Izzo B, De Vivo A, Messa E, Bonifazi F, Poerio A, Luatti S, Giugliano E, Alberti D, Fincato G, Russo D, Pane F, Saglio G and GIMEMA Working Party on Chronic Myeloid: Imatinib and pegylated human recombinant interferon-α2b in early chronic-phase chronic myeloid leukemiaImatinib and pegylated human recombinant interferon-α2b in early chronic-phase chronic myeloid leukemia
    Blood 2004; 104: 4245-4251
    Subjects: CML
  2. Bacher U, Hochhaus A, Berger U, Hiddemann W, Hehlmann R, Haferlachn T, Schoch C: Clonal aberrations in chronic myeloid leukemia independent to the Philadelphia aberration during treatment with imatinib or interferon
    Leukemia 19 (2005) 460-463
    Subjects: CML
  3. Berger U, Maywald O, Pfirrmann M, Lahaye T, Hochhaus A, Reiter A, Hasford J, Heimpel H, Hossfeld DK, Kolb H-J, Löffler H, Pralle H, Queisser W, Hehlmann R and the German CML-Study Group: Gender aspects in chronic myeloid leukaemia: long-term results from randomized studies
    Leukemia 2005; 19: 984-989
    Subjects: CML
  4. Berger U, Engelich G, Reiter A, Hochhaus A, Hehlmann R: The German CML Study Group: Imatinib and beyond-the new CML study IV: A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia
    Ann Hematol 83:258-264 (2005)
    Subjects: CML
  5. Berger U, Maywald O, Pfirrmann M, Lahaye T, Hochhaus A, Reiter A, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, Löffler H, Pralle H, Queisser W, Hehlmann R: German CML-Study Group: Gender aspects in chronic myeloid leukemia: long-term results from randomized studies
    Leukemia 19:984-9 (2005)
    Subjects: CML
  6. Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, Muller-Brusselbach S, Ottmann OG, Duyster J, Hochhaus A, Neubauer A: Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development
    Leukemia 2005;19:1774-82
    Subjects: CML
  7. Crossman LC, Mori M, Hsieh YC, Lange T, Paschka P, Harrington CA, Krohn K, Niederwieser DW, Hehlmann R, Hochhaus A, Druker BJ, Deininger MWN:: In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures
    Haematologica 90:459-464 (2005)
    Subjects: CML
  8. Demehri, S., Paschka, P., Schultheis, B., Lange, T., Koizumi, T., Sugimoto, T., Branford, S., Lim, L.C., Kegel, T., Martinelli, G., Hochhaus, A., Druker, B.J., Deininger, M: E8A2 BCR-ABL: More frequent than other atypical BCR-ABL variants?
    Leukemia 19 (2005) 681-684
    Subjects: CML
  9. Fabarius A, Giehl M, Frank O, Duesberg P, Hochhaus A, Hehlmann R, Seifarth W: Induction of centrosome and chromosome aberrations by imatinib in vitro
    Leukemia 2005;19:1573-8
    Subjects: CML
  10. Giehl M, Fabarius A, Frank O, Hochhaus A, Hafner M, Hehlmann R, Seifarth W: Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability
    Leukemia 2005; 19:1192-7
    Subjects: CML
  11. Gratwohl A: Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation
    Haematologica 2005 Feb;90(2):151
    Subjects: SCT
  12. Gratwohl A, Rosti G, Baccarani M.: Does early stem-cell transplantation have a role in chronic myeloid leukaemia?
    Lancet Oncol 2005; 6: 721-723
    Subjects: CML
  13. Guilhot J, Baccarani M, Clark RE, Cervantes F, Guilhot F, Hochhaus A, Kulikov S, Mayer J, Petzer AL, Rosti G, Rousselot P, Saglio G, Saussele S, Simonsson B, Steegmann JL, Zaritskey A, Hehlmann R.: Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet.
    Blood 2012;119(25):5963-71. [pmid:22508936]
    Subjects: CML
  14. Hasford J, Pfirrmann M, Hochhaus A: How long will chronic myeloid leukaemia patients treated with imatinib mesylate live?
    Leukemia 2005; 19: 497-499
    Subjects: Epidemiology
  15. Hasford J, Pfirrmann M, Shepherd P, Guilhot J, Hehlmann R, Mahon FX, Kluin-Nelemans HC, Ohnishi K, Steegmann JL, Thaler J: The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukaemia treated with interferon-alpha
    Haematologica 2005; 90: 335-340
    Subjects: Epidemiology
  16. Hess G, Bunjes D, Siegert W, Schwerdtfeger R, Ledderose G, Wassmann B, Kobbe G, Bornhauser M, Hochhaus A, Ullmann AJ, Kindler T, Haus U, Gschaidmeier H, Huber C, Fischer T: Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study
    J Clin Oncol 2005;23:7583-93
    Subjects: CML
  17. Kerbauy FR, Storb R, Hegenbart U, Gooley T, Shizuru J, Al-Ali HK, Radich JP, Maloney DG, Agura E, Bruno B, Epner EM, Chauncey TR, Blume KG, Niederwieser D, Sandmaier BM: Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML.
    Leukemia 2005, 19:990-997
    Subjects: SCT
  18. Kruger S, Emig M, Lohse P, Ehninger G, Hochhaus A, Schackert HK: The c-kit (CD117) sequence variation M541L, but not N564K, is frequent in the general population, and is not associated with CML in Caucasians
    Leukemia 2005 Nov 24; Reply to Inokuchi et al. Leukemia. 2005 Nov 24
    Subjects: CML
  19. Lahaye T, Riehm B, Berger U, Paschka P, Müller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, Hochhaus A: 4.5 year follow up of response and resistance in 300 patients with BCR-ABL positive leukemias treated with imatinib in a single center
    Cancer 103 (2005) 1659-1669
    Subjects: CML
  20. Lucy C. Crossman, Motomi Mori, Yi-Ching Hsieh, Thoralf Lange, Peter Paschka, Christina A. Harrington, Knut Krohn, Dietger W. Niederwieser, Rüdiger Hehlmann, Andreas Hochhaus, Brian J. Druker, Michael W.N. Deininger: In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures
    Haematologica 90 (2005) 459-464
    Subjects: CML
  21. Martinelli g, Cilloni D, Rondoni M, Messa F, Ottaviani E, Gottardi E, Piccaluga PP, Malagola M, Soverini S, Merante S, Alimena G, Bosi C, De Vivo A, Rosti G, Giuliana E, Pane F, Izzo B, Testoni N, Paolini S, Rancati F, Bassan R, Mecucci C, Baccarani M, Saglio G: Imatinib mesylate can induce molecular complete remission in idiopathic hypereosinophilic syndrome (HES). A phase II multicentric Italian Clinical Trial
    Blood 2005; 106 (11): abstract 375
    Subjects: CML
  22. Martinelli G, Soverini S, Rosti G, Cilloni D, Baccarani M: Dual tyrosine kinase inhibitors in chronic myeloid leukemia
    Leukemia 2005; 19: 1872-1279
    Subjects: CML
  23. Martinelli G, Soverini S, Rosti G, Cilloni D, Baccarani M: New tyrosine kinase inhibitors in chronic myeloid leukemia
    Haematologica 2005; 90: 534-541
    Subjects: CML
  24. Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B, Berger U, Telford N, Aruliah S, Yin JA, Vanstraelen D, Barker HF, Taylor PC, O'Driscoll A, Benedetti F, Rudolph C, Kolb HJ, Hochhaus A, Hehlmann R, Chase A, Cross NC: The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2
    Cancer Res 65:2662-7 (2005)
    Subjects: AML
  25. Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A, Giannini B, Trabacchi E, Castagnetti F, Testoni N, Luatti S, De Vivo A, Cilloni D, Izzo B, Fava M, Abruzzese E, Alberti D, Pane F, Saglio G, Baccarani M: ABL mutation in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to Imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA working party on chronic myeloid leukemia
    J Clin Oncol 2005; 23: 4100-4109
    Subjects: CML
  26. Walz C, Chase A, Schoch C, Weisser A, Schlegel F, Hochhaus A, Fuchs R, Schmitt-Gräff A, Hehlmann R, Cross NC, Reiter A: The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1
    Leukemia 19:1005-9 (2005)
    Subjects: CML

 

Print this Document   Sitemap   Contact  
EUTOS
EUTOS for CML is a unique collaboration between the European LeukemiaNet and Novartis Oncology in Europe More ...


 
top